Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Core Insights - Nurix Therapeutics, Inc. is set to host a live webcast on December 8, 2025, to present new clinical data from its ongoing Phase 1a/1b trial of bexobrutideg, a BTK degrader program, along with a corporate update [1][2] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation medicines for oncology and autoimmune diseases [5] - The company’s pipeline includes BTK degraders and CBL-B inhibitors, with ongoing collaborations with major pharmaceutical companies like Sanofi and Gilead [5] Clinical Trial Information - Bexobrutideg (NX-5948) is currently being evaluated in the DAYBreak CLL-201 clinical trial, a pivotal Phase 2 study for patients with relapsed or refractory chronic lymphocytic leukemia [4] - The NX-5948-301 Phase 1a/1b trial is also ongoing for patients with relapsed or refractory B cell malignancies [4] Webcast Details - The webcast will feature presentations from key figures including Dr. Alvaro Alencar and Dr. Arthur T. Sands, discussing clinical data and Nurix's development strategy [2][3]